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(US/UK). Patients also provided their opinions of current CT
with DFO to ensure that no major concepts were omitted.
RESULTS: The literature review revealed no IO or CT speciﬁc
questionnaires, though several articles recounted DFO’s incon-
venience and impact. Patient and clinician interviews suggested
that patients were most concerned about the efﬁcacy, side effects,
convenience and costs of any new IO treatment. Satisfaction with
DFO was low, primarily due to local site reactions, inconve-
nience, and the constraining nature of the therapies. Presented
with a hypothetical oral CT, patients unanimously preferred oral
CT. A 40-item questionnaire was developed that assessed
patients’ expectations of and satisfaction with attributes identi-
ﬁed as important including efﬁcacy, safety, convenience and side
effects, along with costs, overall satisfaction, treatment impact,
patient compliance, and preferences. Results from the content
validity testing resulted in additions to the instructions and the
rewording of six items. CONCLUSIONS: To accurately assess
satisfaction, patient input should be obtained. In the absence of
real-life experience with the proposed therapy, unbiased hypo-
thetical product proﬁles were used to elicit the dimensions
important to patients, and this is consistent with established
methods. Psychometric validation is currently underway.
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OBJECTIVE: Item response bias (also called differential item
functioning, DIF) in Instrumental Activities of Daily Living
(IADL) occurs when members of different groups possessing the
same disability level do not have the same probability of
responding positively for a given item(s). This study aimed to
identify the extent of DIF by gender, age, ethnicity and demen-
tia groups in IADL estimates in Asian (Chinese, Malay and
Indian) elderly subjects. METHODS: Data of the 2003 National
Mental Health Survey were analyzed from 1072 non-institu-
tionalized elderly subjects using multiple indicator–multiple
cause latent variable (MIMIC) modeling. RESULTS: Given the
same functional level, older elderly were less likely to report
receiving help with preparing meals; men were more likely to
report receiving help with preparing meals, doing laundry, and
taking medication; Malays were more likely to report receiving
help with using telephone; and demented elderly were more
likely to report receiving help with using telephone, managing
money, taking medications, and “getting around”. The impact
of DIF on group differences was highest for gender (54.0%), eth-
nicity (42.9%), dementia (14.7%) and age (2.4%). CONCLU-
SION: Item-response bias in IADL estimates by gender, age,
ethnicity and dementia should be considered in direct compar-
isons of disability status among population groups.
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OBJECTIVES: To conduct a cost analysis of current competing
strategies for the management of patients with closed and open
grade I tibial shaft fractures, from both a governmental and soci-
etal perspective. METHODS: Our cost analysis was performed
for four competing treatment strategies for management of
closed or grade I open tibial fractures: 1). casting alone; 2).
casting with therapeutic ultrasound; 3). operative treatment with
non-reamed intramedullary nailing; and 4). operative treatment
with reamed intramedullary nailing. The time to radiographic
fracture union was used as the measure of effectiveness. Given
the multiple clinical alternatives, each with the potential to result
in a number of outcomes, a decision tree was used to perform
all cost analyses. Sensitivity analysis was conducted through
Monte Carlo simulations. RESULTS: From a governmental per-
spective the mean associated costs were USD $3365 (standard
deviation [SD] ± 1425) for operative management by reamed
intramedullary nailing, $5041 (SD ± 1363) for operative man-
agement by non-reamed intramedullary nailing, $5017 (SD ±
1370) for casting, and $5312 (SD ± 1474) for casting with 
therapeutic ultrasound. From a societal perspective the mean
associated costs were ($12,449; SD ± 4894) for reamed
intramedullary nailing, ($13,266; SD ± 3692) for casting with
therapeutic ultrasound, ($15,571; SD ± 4293) for operative man-
agement by non-reamed intramedullary nailing, and ($17,343;
SD ± 4784) for casting alone. CONCLUSIONS: Our preliminary
cost analysis suggests that, from both a governmental and soci-
etal perspective, reamed intramedullary nailing is the treatment
of choice for closed and open grade I tibial shaft fractures.
However, there is evidence that, from a societal perspective,
treatment of low energy tibial fractures with therapeutic 
ultrasound and casting may also be an economically-sound 
intervention.
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OBJECTIVES: To assess, in the Belgian setting, the costs, efﬁ-
cacy, and cost-effectiveness of zoledronic acid 5mg (Aclasta)
versus conventional therapies (tiludronate (Skelid), pamidronate
(Aredia), and risedronate (Actonel)) in the management of
patients with Paget’s disease of bone (PDB). METHODS: Based
on efﬁcacy data from pivotal zoledronic acid 5mg clinical trials
and the literature, a decision tree model was developed to reﬂect
the treatment path with the different drugs compared. This
model takes into account four health states and links efﬁcacy
data to Belgian resource use data. It covers a 2-year time horizon.
The outcome measure chosen is time in response, deﬁned as time
in which serum alkaline phosphatase is controlled. Direct
medical costs, from the perspective of the health care payer
(INAMI/RIZIV) were considered and discounting was applied in
the second year. The consumption of medical resources (drug
treatments including administration costs, laboratory tests, and
physician consultations) was assessed via expert opinion.
RESULTS: Over two years, the expected average numbers of
months in response for patients treated with zoledronic acid 5
mg and conventional treatments (tiludronate, pamidronate, and
risedronate) are: 20.9 months; 11.1 months; 9.3 months; and
16.2 months, respectively. Over this period, the expected average
costs for patients treated with zoledronic acid 5mg and conven-
tional treatments (tiludronate, pamidronate, and risedronate)
are: €686; €1525; €1245; and €793, respectively. Hence, zole-
dronic acid 5mg dominates all the other bisphosphonates com-
pared, i.e. zoledronic acid 5mg is less costly and more effective.
